Patents Assigned to HealthPartners Research & Education
-
Patent number: 11559579Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: September 25, 2020Date of Patent: January 24, 2023Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
-
Patent number: 10987423Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: December 4, 2020Date of Patent: April 27, 2021Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
-
Patent number: 10967061Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: May 10, 2019Date of Patent: April 6, 2021Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
-
Patent number: 10314911Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: April 6, 2015Date of Patent: June 11, 2019Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for Advancement of Military Medicine, Inc.Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
-
Patent number: 10279012Abstract: Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and/or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and/or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism.Type: GrantFiled: March 10, 2014Date of Patent: May 7, 2019Assignee: HealthPartners Research & EducationInventor: William H. Frey, II
-
Patent number: 9821149Abstract: The present invention is directed to methods for reducing systemic absorption of therapeutic compounds or agents while enhancing efficiency of delivery and targeting of intranasal administration of such compounds or agents to the central nervous system. More specifically, use of ultrasound technology in conjunction with intranasal delivery of a therapeutic compound, or pharmaceutical composition, wherein the intranasal delivery is preferably to the upper one third of a patient's nasal cavity, thereby reducing therapeutic compound or agent absorption into the blood. At the same time, the present invention results in reducing the delivery of therapeutic compounds and/or agents to the peripheral tissues, increases therapeutic delivery of the compounds and/or agents to the central nervous system generally, and increases targeting of the therapeutics and/or agents to specific target regions within the central nervous system.Type: GrantFiled: October 12, 2012Date of Patent: November 21, 2017Assignee: HealthPartners Research & EducationInventor: William H. Frey, II
-
Patent number: 9707274Abstract: Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.Type: GrantFiled: September 30, 2013Date of Patent: July 18, 2017Assignee: HealthPartners Research & EducationInventor: William H. Frey, II
-
Patent number: 9339638Abstract: The invention provides a system and method for delivering antibiotic powder to a surgical wound that reduces the likelihood of contamination. A pre-packaged, sterile antibiotic powder delivery system comprises a container; a measured dosage of an antibiotic powder disposed within the container; and a sieve top attached to the top of the container, wherein the container and sieve top are sealed as a unit in a sterile packaging. To use the delivery system in the sterile surgery or operating room environment, the delivery system is removed from the sterile packaging. The delivery system is shaken over the surgical wound for a reasonable amount of time to cover the entire wound, avoid surgeon fatigue at the end of surgery, and avoid prolonging the total time the wound is open.Type: GrantFiled: March 14, 2013Date of Patent: May 17, 2016Assignee: HealthPartners Research & EducationInventor: Matthew M. Kang
-
Patent number: 9249424Abstract: The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods.Type: GrantFiled: December 11, 2013Date of Patent: February 2, 2016Assignees: Regents of the University of Minnesota, HealthPartners Research & EducationInventors: Daniel A. Wolf, William H. Frey, II, R. Scott McIvor, Leah R. Hanson
-
Publication number: 20140255384Abstract: Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and/or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and/or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Applicant: HealthPartners Research & EducationInventor: William H. Frey, II
-
Publication number: 20140171491Abstract: The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods.Type: ApplicationFiled: December 11, 2013Publication date: June 19, 2014Applicants: HealthPartners Research & Education, Regents of the University of MinnesotaInventors: Daniel A. Wolf, William H. Frey, II, R. Scott McIvor, Leah R. Hanson
-
Publication number: 20140031280Abstract: Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.Type: ApplicationFiled: September 30, 2013Publication date: January 30, 2014Applicant: HealthPartners Research & EducationInventor: William H. Frey, II
-
Patent number: 8609088Abstract: The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods.Type: GrantFiled: May 7, 2012Date of Patent: December 17, 2013Assignees: Regents of the University of Minnesota, HealthPartners Research & EducationInventors: Daniel A. Wolf, William H. Frey, II, R. Scott McIvor, Leah R. Hanson
-
Patent number: 8501691Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.Type: GrantFiled: May 24, 2012Date of Patent: August 6, 2013Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research & EducationInventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
-
Publication number: 20130096488Abstract: The present invention is directed to methods for reducing systemic absorption of therapeutic compounds or agents while enhancing efficiency of delivery and targeting of intranasal administration of such compounds or agents to the central nervous system. More specifically, use of ultrasound technology in conjunction with intranasal delivery of a therapeutic compound, or pharmaceutical composition, wherein the intranasal delivery is preferably to the upper one third of a patient's nasal cavity, thereby reducing therapeutic compound or agent absorption into the blood. At the same time, the present invention results in reducing the delivery of therapeutic compounds and/or agents to the peripheral tissues, increases therapeutic delivery of the compounds and/or agents to the central nervous system generally, and increases targeting of the therapeutics and/or agents to specific target regions within the central nervous system.Type: ApplicationFiled: October 12, 2012Publication date: April 18, 2013Applicant: HealthPartners Research & EducationInventor: HealthPartners Research & Education